Zhi Byed 11

also known as ZB11

Developed for: hemorrhagic disease
Investigated by: Bill and Melinda Gates Foundation · Fogarty International Center of the National Institute of Health · Global Network for Women's and Children's Health Research · Health Bureau Tibet Autonomous Region · NICHD Global Network for Women's and Children's Health · National Cancer Institute (NCI)
+6 more
· National Center for Complementary and Integrative Health (NCCIH) · National Institute of Dental and Craniofacial Research (NIDCR) · One Heart Project · RTI International · University of California, San Francisco · University of Utah

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT00147420	Sep 2005 → Mar 2007	hemorrhagic disease	NICHD Global Network for Women's and Children's Health	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Zhi Byed 11	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00147420 ↗
Known as	ZB11	“RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet” NCT00147420 ↗
Modality	Traditional medicine (herbal / TCM)	“traditional Tibetan drug” NCT00147420 ↗
Route	Oral	“prophylactic oral ZB 11 administered at the beginning of the second stage of labor” NCT00147420 ↗